<DOC>
	<DOCNO>NCT01196507</DOCNO>
	<brief_summary>Patients cirrhosis portal hypertension age 18 75 year small esophageal varix without red color sign bleed previously enrol . After baseline evaluation , participant randomize receive either Placebo Carvedilol 12.5 mg BD . After randomization follow one year . The primary endpoint study proportion patient develop large varix ( Gd 3 Gd 4 ) 1 year group . The secondary endpoint survival , reduction HVPG , change CTP MELD score &amp; adverse event .</brief_summary>
	<brief_title>Early Primary Prophylaxis Esophageal Varices</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Patients cirrhosis portal hypertension age 18 75 year small esophageal varix without red color sign bleed previously . Any contraindication betablockers Any EVL sclerotherapy within last 3 month Child Turcotte Pugh ( CTP ) score &gt; 12 , refractory ascites , hepatorenal syndrome Any past history surgery portal hypertension Significant cardio pulmonary comorbidity Any malignancy affect survival . Active alcohol abuse last intake â‰¤ 4 week avoid possibility ongoing alcohol hepatitis . Past history surgery portal hypertension Uncontrolled diabetes Peripheral vascular disease Refusal participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>